证券代码：300341 证券简称：麦克奥迪 公告编号：2024-030 麦克奥迪（厦门）电气股份有限公司 第五届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议出席情况 表决结果：3 票赞成、0 票反对、0 票弃权。 公司监事会对公司董事会编制完成的《麦克奥迪(厦门)电气股份有限公司 2024 年第三季度报告》进行了认真的审阅，并提出如下审核意见： （1）《麦克奥迪(厦门)电气股份有限公司 2024 年第三季度报告》的编制和审 议程序符合法律法规、规范性文件以及公司章程和公司内部管理制度的各项规定； （2）《麦克奥迪(厦门)电气股份有限公司 2024 年第三季度报告》的内容和格 式符合中国证监会和深圳证券交易所的各项规定，所包含的信息能从各个方面真 实准确反映公司 2024 年第三季度的财务状况和经营成果等事项； （3）在公司监事会提出本意见前，未发现参与《麦克奥迪(厦门)电气股份有 限公司 2024 年第三季度报告》编制和审议的人员有违反保密规定的行为。 三、备查文件 1、第五届监事会第九次会议决议。 1 麦克奥迪（厦门）电 ...

证券代码：300341 证券简称：麦克奥迪 公告编号：2024-029 麦克奥迪（厦门）电气股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议出席情况： 麦克奥迪（厦门）电气股份有限公司（以下称"公司"）第五届董事会第十一 次会议（以下简称"本次会议"）通知于 2024 年 10 月 16 日以邮件方式发出。本 次会议于 2024 年 10 月 22 日在公司会议室以现场方式召开。本次会议应参加董 事 12 名，实际参加董事 12 名。本次会议符合《中华人民共和国公司法》及《公 司章程》的规定。本次会议由公司董事长杨文良先生主持。 表决结果：12 票赞成、0 票反对、0 票弃权。 为进一步提升公司环境、社会与公司治理（ESG）管理水平，健全公司 ESG 管理体系，公司将董事会下设的"董事会战略委员会"调整为"董事会战略与 ESG 委员会"，在原有职责基础上增加 ESG 相关职责。将原《董事会战略委员会工作 细则》修订为《董事会战略与 ESG 委员会工作细则》。本次调整仅为董事会战略 委员会名称和职责调整，其 ...

Financial Performance - Revenue for Q3 2024 was CNY 341,700,120.71, a decrease of 2.50% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was CNY 44,802,710.62, an increase of 1.55% year-on-year[3] - Net profit excluding non-recurring gains and losses for Q3 2024 was CNY 44,307,515.25, a slight decrease of 0.17% compared to the previous year[3] - Total operating revenue for Q3 2024 was ¥996,169,384.90, a decrease of 3.4% compared to ¥1,028,419,402.31 in the same period last year[18] - The net profit for the third quarter of 2024 was CNY 125,968,441.87, an increase from CNY 122,787,260.56 in the same period last year, representing a growth of approximately 2%[19] - The total profit for the quarter was CNY 147,006,656.29, compared to CNY 146,044,085.28 in the previous year, indicating a slight increase of about 0.7%[19] - The operating profit for the quarter was CNY 145,768,698.71, which is relatively stable compared to CNY 146,062,512.39 from the previous year[19] Assets and Equity - Total assets at the end of Q3 2024 reached CNY 2,424,379,146.88, reflecting a growth of 5.72% from the end of the previous year[3] - Shareholders' equity attributable to the parent company was CNY 1,777,861,220.68, up 5.31% from the end of last year[3] - The total assets of the company reached ¥2,424,379,146.88, up 5.7% from ¥2,293,277,799.77[17] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 165,931,004.75, an increase of 7.83% year-on-year[3] - Cash flow from operating activities showed a net increase of CNY 165,931,004.75, compared to CNY 153,877,222.93 in the previous year, marking an increase of about 7.5%[21] - The cash and cash equivalents at the end of the period amounted to CNY 796,228,461.84, an increase from CNY 621,191,130.91 at the end of the previous year[22] - Net increase in cash and cash equivalents was 89.22%, reaching 5,193.07 million, due to higher net cash flow from investment and operating activities[10] Expenses - The company reported a significant increase in financial expenses by 2026.50% due to increased interest income from fixed deposits and exchange rate impacts[8] - Other income increased by 1757.34% to CNY 235.83 million, driven by policy incentives and asset gains[8] - Research and development expenses rose by 22.25% to 5,541.92 million, reflecting increased investment in new products and materials[10] - Research and development expenses for Q3 2024 were ¥55,419,207.71, an increase of 22.3% from ¥45,331,327.81 in the previous year[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,612[11] - Beijing Yizhuang Investment Holding Co., Ltd. held the largest share at 29.57%, with 152,997,984 shares[11] - The top ten shareholders collectively hold significant stakes, with the largest being 29.57%[11] Investment Activities - Investment income decreased significantly by 527.70% to -63.48 million, primarily due to losses from joint ventures[10] - Net cash flow from investing activities improved by 24.30% to -6,930.03 million, as payments for the Xiang'an Phase III project decreased year-on-year[10] - The company recorded a decrease in investment activities cash flow, with a net cash outflow of CNY 69,300,330.01, compared to CNY 91,547,167.84 in the previous year[22] Strategic Focus - The company has a strategy focused on expanding its R&D efforts and enhancing product offerings to drive future growth[10]

证券代码：300341 证券简称：麦克奥迪 公告编号：2024-026 麦克奥迪（厦门）电气股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、公司股票交易异常波动的情况 麦克奥迪（厦门）电气股份有限公司（以下简称"公司"）股票（证券简称： 麦克奥迪；证券代码：300341）交易价格连续三个交易日内（分别为 2024 年 10 月 14 日、2024 年 10 月 15 日、2024 年 10 月 16 日）日收盘价格涨幅偏离值累计 达到 30%以上，根据深圳证券交易所相关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况的说明 针对公司股票交易异常波动情况，公司就相关事项进行了核实，现就相关情 况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、公司目前的经营情况及内外部经营环境未发生重大变化； 6、公司不存在违反公平信息披露规定的情形。 三、关于不存在应披露而未披露信息的说明 公司董事会确认，公 ...

（二）社会上存在的已经或将给公司造成不良影响的传言或信息； 麦克奥迪(厦门)电气股份有限公司 舆情管理制度 （一）报刊、电视、网络等媒体对公司进行的负面报道； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大 影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动，使 公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格异 常波动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 1 第一条 为规范麦克奥迪(厦门)电气股份有限公司(以下简称"公司")应对各类舆情的能 力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股票及其 衍生品种、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者和 公司的合法权益，根据《深圳证券交易所创业板股票上市规则》等相关法律法 规的规定和《麦克奥迪(厦门)电气股份有限公司章程》的规定，结合公司实际情 况，特制定本制度。 第二条 本制度所称舆情包括： 第四条 公司应对各类舆情实行统一领导、统一组织、 ...

| | 厦门骁科码生物 科技有限公司 | 公司间接持股 5%以上 股东陈沛欣能实施重 | 预付账款 | 3.43 | | | 3.43 | - | 技术服务费 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 大影响的企业 | | | | | | | | | | | 厦门骁科码生物 科技有限公司 | 公司间接持股 5%以上 股东陈沛欣能实施重 大影响的企业 | 应收账款 | - | 9.67 | | 7.91 | 1.76 | 技术服务费 | 经营性往来 | | | 厦门骁科码生物 | 公司间接持股 5%以上 股东陈沛欣能实施重 | 其他应收款 | - | 1.17 | | 0.97 | 0.19 | 房屋及物业费 | 经营性往来 | | | 科技有限公司 | 大影响的企业 | | | | | | | | | | | 厦门斯玛特思智 能电气有限公司 | 联营企业 | 应收账款 | 29.25 | - | | - | 29.25 | 销售商品 | 经营性往来 | | 总计 | - | - | - ...

证券代码：300341 证券简称：麦克奥迪 公告编号：2024-023 麦克奥迪（厦门）电气股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议出席情况： 麦克奥迪（厦门）电气股份有限公司（以下称"公司"）第五届董事会第十次 会议（以下简称"本次会议"）通知于 2024 年 08 月 12 日以邮件方式发出。本次 会议于 2024 年 08 月 24 日在公司会议室以现场方式召开。本次会议应参加董事 12 名，实际参加董事 12 名。本次会议符合《中华人民共和国公司法》及《公司 章程》的规定。本次会议由公司董事长杨文良先生主持。 二、议案审议情况： 1、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 表决结果：12 票赞成、0 票反对、0 票弃权。 公司董事认真审阅了《麦克奥迪(厦门)电气股份有限公司 2024 年半年度报 告》全文及摘要，该报告的编制和审议程序符合法律法规、规范性文件以及公司 章程的规定，其内容与格式符合中国证监会和深圳证券交易所的各项规定，报告 内容真实、准确和完整地反映了公司 ...

Financial Performance - Revenue for the reporting period was RMB 654.47 million, a decrease of 3.46% compared to the same period last year[11] - Net profit attributable to shareholders of the listed company was RMB 77.48 million, an increase of 2.59% year-on-year[11] - Net cash flow from operating activities was RMB 112.30 million, a significant increase of 48.80% compared to the same period last year[11] - Basic earnings per share were RMB 0.1497, up 1.77% year-on-year[11] - Total assets at the end of the reporting period were RMB 2.35 billion, an increase of 2.43% compared to the end of the previous year[11] - Net assets attributable to shareholders of the listed company were RMB 1.74 billion, an increase of 2.89% compared to the end of the previous year[11] - Consolidated operating revenue reached 654,469,264.19 yuan, a year-on-year decrease of 3.46%[22] - Net profit attributable to shareholders of the listed company was 77,475,534.06 yuan, a year-on-year increase of 2.59%[22] - Basic earnings per share were 0.1497 yuan, a year-on-year increase of 1.77%[22] - Revenue for the reporting period was RMB 654.47 million, a decrease of 3.46% year-over-year[36] - Net cash flow from operating activities increased by 48.80% to RMB 112.30 million, driven by reduced procurement expenditures[36] - Total operating revenue for the first half of 2024 was 654,469,264.19 RMB, a decrease of 3.47% compared to 677,958,564.58 RMB in the same period of 2023[103] - Operating profit for the first half of 2024 was 93,888,085.08 RMB, an increase of 2.95% compared to 91,198,679.34 RMB in the same period of 2023[104] - Net profit for the first half of 2024 was 95,287,821.25 RMB, an increase of 4.57% compared to 91,125,754.67 RMB in the same period of 2023[104] - Net profit attributable to parent company shareholders increased to 77,475,534.06 RMB, up 2.6% compared to 75,519,036.31 RMB in the same period last year[105] - Operating income rose to 11,536,987.97 RMB, a 43.6% increase from 8,036,641.10 RMB in the previous year[107] - Net cash flow from operating activities grew to 112,295,364.19 RMB, up 48.8% from 75,468,589.30 RMB in the same period last year[109] - Investment income surged to 65,000,000.00 RMB, compared to 0.00 RMB in the previous year[107] - Interest income increased significantly to 1,835,257.63 RMB, a 14.2x rise from 120,667.61 RMB in the same period last year[107] - Total comprehensive income reached 82,693,648.26 RMB, down 11.8% from 93,796,531.01 RMB in the previous year[105] - Basic earnings per share increased to 0.1497 RMB, up 1.8% from 0.1471 RMB in the same period last year[105] - Cash received from selling goods and providing services decreased to 631,648,361.55 RMB, down 18.2% from 771,746,801.47 RMB in the previous year[109] - Taxes and surcharges increased to 1,048,800.49 RMB, up 23.3% from 850,348.53 RMB in the same period last year[107] - Other comprehensive income after tax decreased to 2,191,427.30 RMB, down 87.0% from 16,858,377.61 RMB in the previous year[105] - Investment activities generated a net cash outflow of RMB 39.34 million in H1 2024, compared to RMB 60.90 million in H1 2023[110] - Cash and cash equivalents increased by RMB 26.88 million in H1 2024, reaching a total of RMB 771.17 million at the end of the period[110] - Parent company's investment activities resulted in a net cash inflow of RMB 64.37 million in H1 2024, a significant improvement from a net outflow of RMB 4.96 million in H1 2023[112] - Parent company's cash and cash equivalents increased by RMB 6,723.77 in H1 2024, totaling RMB 91.86 million at the end of the period[112] - Consolidated owner's equity at the end of H1 2024 was RMB 1.81 billion, with minority shareholders' equity accounting for RMB 120.10 million[113] - The company's total comprehensive income for the period was RMB 79,666,961.36, with a net profit attributable to the parent company of RMB 77,475,534.06[114] - The company's total equity at the end of the period was RMB 1,857,386,935.02, an increase of RMB 49,127,161.20 compared to the beginning of the period[114] - The company's capital reserve increased by RMB 2,148,317.80 due to share-based payments[114] - The company's undistributed profit decreased by RMB 36,218,722.87 due to profit distribution[114] - The company's special reserve increased by RMB 3,212,474.99, with an extraction of RMB 4,058,002.04 and usage of RMB 845,527.05[114] - The company's total equity at the end of the previous year was RMB 1,691,779,983.75[117] - The company's capital reserve at the beginning of the period was RMB 69,908,659.46[114] - The company's undistributed profit at the beginning of the period was RMB 1,030,597,629.12[114] - The company's minority shareholders' equity at the end of the period was RMB 120,415,672.67[114] - The company's total equity at the beginning of the period was RMB 1,808,259,773.82[114] - Initial balance at the beginning of the period was RMB 513,393,236.00[118] - Total comprehensive income for the period was RMB 16,858,377.61[118] - Owner's capital contribution during the period was RMB 5,451,015.52[118] - Total profit distribution for the period was RMB -5,037,672.98[118] - Total increase in equity during the period was RMB 98,196,426.34[118] - The company's total owner's equity at the end of the period was RMB 1,789,976,410.05, with a significant portion attributed to undistributed profits of RMB 1,656,944,000.20[119] - The company's capital reserve increased by RMB 2,172,653.96 during the period, primarily due to equity incentives[122] - The company's comprehensive income for the period was RMB 63,365,015.16, contributing to the increase in owner's equity[122] - The company distributed RMB 36,218,722.87 to shareholders during the period, reducing the undistributed profits[122] - The company's total owner's equity at the end of the period was RMB 862,034,550.84, with a capital reserve of RMB 68,275,920.63[123] - The company's total owner's equity at the beginning of the year was RMB 798,674,770, with a capital reserve of RMB 59,308,481 and undistributed profits of RMB 197,766,610[124] - The company's comprehensive income for the period decreased by RMB 7,179,241.17, leading to a total decrease in owner's equity of RMB 1,712,317.68[124] - The company received RMB 5,466,923.49 from owner contributions, primarily through share-based payments[125] - The company's total owner's equity at the end of the period was RMB 796,962,456.62, with a capital reserve of RMB 64,775,404.57 and undistributed profits of RMB 190,587,374.00[125] Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to RMB 5.39 million, primarily from government subsidies and other non-operating income[14] - Non-recurring gains and losses amounted to 305,572.25, with an income tax impact of 912,020.72 and a minority interest impact of 105,316.56, totaling 5,388,911.93[15] Industry Trends and Opportunities - The medical industry is experiencing growth due to increased demand for early diagnosis and precision medicine, driven by rising health awareness and the implementation of hierarchical medical systems[16] - Molecular pathology technology is becoming crucial in tumor, infectious disease, and genetic disease detection, with high-throughput, fully automated pathology sample processing systems and AI integration emerging as key competitive areas[16] - The optical industry is benefiting from the growing demand for optical components in AI, IoT, and emerging markets like AR/VR and biometrics, with microscopy playing a vital role in nanotechnology and semiconductor inspection[17] - National policies are supporting the localization of scientific instruments, with a focus on developing advanced microscopy and analytical instruments, and increasing the proportion of domestic procurement in government institutions[17] - The electrical industry is facing opportunities and challenges from the further development of terminal electrification and clean energy supply, with increasing demand for electrical equipment globally[18] - Epoxy insulation components are in high demand due to their critical role in power transmission, substations, and power plants, with growing markets in India, Southeast Asia, and North America[18] - Data centers and AI computing infrastructure are driving the need for global grid investment and transformation, further boosting the demand for electrical equipment[18] Digital and Medical Innovations - The company's "Digital Medical" platform has covered over 3,000 hospitals nationwide and completed nearly 1 million remote difficult case diagnoses[19] - The company established a "Suihua City People's Hospital Pathology Remote Consultation Center" and signed contracts with Lanzhou University First Hospital Donggang Campus and its affiliated hospitals[19] - The company launched a pathology slide scanning image analysis system (TIS) with AI-assisted diagnostic functions, enriching the DNA product line and supporting cervical cancer screening[19] - The company's digital pathology platform serves over 3,000 hospitals nationwide, enhancing diagnostic accuracy and efficiency[31] - The company holds 15 invention patents, 9 utility models, and 18 software copyrights as of the reporting period[31] - The company has developed innovative products such as the "digital built-in microscope" and "digital microscope interactive classroom"[31] - Expansion into industrial applications includes products like EasyZoom ultra-depth digital microscope and PA53 research-grade microscope series[31] - The company has established a strong R&D network with international collaborations, including partnerships with German and Canadian research institutions[31] - The company operates a postdoctoral research workstation and a Fujian Provincial Academician Expert Workstation[31] - The digital pathology platform integrates remote consultation, education, and quality control, significantly improving service levels in healthcare[31] - The company's platform is recognized as one of the most efficient and effective remote consultation platforms in China[31] - The company continues to strengthen its technological innovation capabilities through industry-academia-research collaboration[31] Smart Optics and Electrical Business - The "Smart Optics" business expanded its product applications to industrial inspection and scientific research, with operations in 109 countries and regions[20] - The company successfully collaborated with a U.S. company in multi-channel fluorescence scanning detection, aiming for FDA certification[20] - Strategic products like EasyZoom ultra-depth, PA53 fluorescence microscope, and Easyscan scanner achieved new sales breakthroughs in the domestic market[21] - The company participated in major exhibitions such as the 2024 Spring Higher Education Exhibition and SEMICON, enhancing brand awareness[21] - The "Smart Electrical" business achieved record-high performance by leveraging global energy transformation opportunities[21] - The company focused on upgrading traditional insulation products to be more environmentally friendly, compact, and intelligent, integrating IoT technologies[21] - The company's core insulation components are widely recognized by leading global power equipment manufacturers like Schneider, ABB, and Hitachi Energy[21] Overseas Market Performance - Overseas market revenue achieved 116% of the budget, with a year-on-year growth of 27%[22] R&D and Innovation - The company plans to increase R&D investment and accelerate the landing of new products, materials, processes, and markets[23] - The company aims to strengthen capital platform construction and promote industry chain joint ventures and cooperation[23] - The company will accelerate digital transformation to improve efficiency and quality[23] - The company will focus on introducing and cultivating industry-leading talents to optimize the human resource structure[23] - The company will reinforce three strategic guarantees: party building, safety, and culture to drive high-quality development[23] - R&D investment increased by 16.75% year-over-year, with a focus on accelerating technology leadership talent development[31] - R&D investment increased by 16.75% to RMB 34.50 million, reflecting continued focus on innovation[36] - The company holds 90 invention patents, 80 utility and design patents, and 101 software copyrights, showcasing strong intellectual property[32] - The company's R&D team consists of over 300 professionals, including experts from global industry leaders like Zeiss and Leica[34] - The company will increase R&D investment, strengthen industry-academia collaboration, and optimize new product development processes to maintain market competitiveness[52] Medical Device and Diagnostic Products - The company holds 71 valid medical device registration certificates as of June 30, 2024[24] - The company has a range of long-term effective in vitro diagnostic reagents, including buffer solutions, sample density separation fluids, and cleaning fluids, all classified under Class I medical devices[25] - Newly developed reagents such as DNA ploidy analysis staining solution and cell analysis staining solution are designed for advanced diagnostic applications, including computer-aided diagnosis and image analysis[25] - The company has introduced a series of immunohistochemical antibody reagents, including Ki-67, BCL-2, and BCL-6, which provide auxiliary diagnostic information for pathologists[25][26] - A variety of CD marker antibody reagents (e.g., CD3, CD5, CD10) are available for immunohistochemical staining, aiding in pathological diagnosis without guiding clinical medication or companion diagnostics[26] - CDX-2 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][40] - E-Cadherin antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][41] - GATA3 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][42] - MSH2 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][43] - MSH6 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][44] - p16 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][45] - p40 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][46] - p53 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][47] - p63 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[27][48] - PMS2 antibody reagent (immunohistochemistry) is classified as a Class I in vitro diagnostic reagent, providing auxiliary diagnostic information for pathologists[28][50] Financial Position and Assets - Total assets at the end of the reporting period were RMB 2.35 billion, an increase of 2.43% compared to the end of the previous year[11] - Net assets attributable to shareholders of the listed company were RMB 1.74 billion, an increase of 2.89% compared to the end of the previous year[11] - Total assets as of the end of the first half of 2024 were 971,772,237.85 RMB, a slight decrease of 0.01% compared to 971,873,871.89 RMB at the end of the first half of 2023[101][102] - Total liabilities as of the end of the first half of 2024 were 109,737,687.01 RMB, a decrease of 21.16% compared to 139,158,267.30 RMB at the end of the first half of 2023[102] - Total equity as of the end of the first half of 2024 was 862,034,550.84 RMB, an increase of 3.52% compared to 832,715,604.59 RMB at the end of the first half of 2023[102] - Prepayments as of the end of the first half of 2024 were 563,055.57 RMB, an increase of 257.78% compared to 157,394.99 RMB at the end of the first half of 2023[101] - Other receivables as of the end of the first half of 2024 were 3,362,393.42 RMB, an increase of 92.49% compared to 1,746,920.79 RMB at the end of the first half of 2023[101] - Financial expenses for the first half of 2024 were -11,333,944.74 RMB, a significant decrease compared to -910,765.82 RMB in the same period of 2023[104] - Total assets increased to 2,348,905,724.38 yuan, up from 2,293,277,799.77 yuan at the beginning of the period[97][99] - Net profit attributable to the parent company rose to 1,071,854,440.31 yuan, compared to 1,030,597,629.12 yuan at the start of the period[99] - Cash and cash equivalents grew to 771,317,731.63 yuan, up from 744,506,

证券代码：300341 证券简称：麦克奥迪 公告编号：2024-025 麦克奥迪（厦门）电气股份有限公司 关于新增2024年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）关联交易概述 1、根据麦克奥迪（厦门）电气股份有限公司（以下简称"公司"）日常经 营实际需要，结合 2023 年度公司关联交易的实际情况和公司业务发展的需要， 公司 2024 年与关联方发生日常关联交易预计总额不超过人民币 3,884.00 万元。 2、根据公司及其控股子公司日常经营实际需要，结合 2024 年度公司关联交 易的实际情况和公司业务发展的需要，公司 2024 年新增与关联方发生日常关联 交易预计总额不超过人民币 1,000.00 万元。2024 年 08 月 24 日，公司第五届董 事会第十次会议审议通过了《关于新增 2024 年度日常关联交易预计的议案》， 关联董事回避表决。本次日常关联交易预计事项在提交董事会审议前已经独立董 事专门会议 2024 年第二次会议审议通过。根据《深圳证券交易所创业板股票上 市规则》和《公 ...

麦克奥迪（厦门）电气股份有限公司 证券代码：300341 证券简称：麦克奥迪 公告编号：2024-024 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、会议出席情况 麦克奥迪（厦门）电气股份有限公司（以下称"公司"）第五届监事会第八 次会议（以下简称"本次会议"）通知于 2024 年 08 月 12 日以邮件方式发出。本 次会议于 2024 年 08 月 24 日在公司会议室以现场方式召开。本次会议应参加监 事 3 名，实际参加监事 3 名。本次会议符合《中华人民共和国公司法》及《公司 章程》的规定。本次会议由公司监事会主席韩勇先生主持。 二、议案审议情况 1、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 表决结果：3 票赞成、0 票反对、0 票弃权。 公司监事会对公司董事会编制完成的《麦克奥迪(厦门)电气股份有限公司 2024 年半年度报告》全文及摘要进行了认真的审阅，并提出如下审核意见： （1）《麦克奥迪(厦门)电气股份有限公司 2024 年半年度报告》全文及摘要的 编制和审议程序符合法律法规、规范性文件以及公司章程和公司内部管理制度 ...